 |
|
|
| |
Anti-Fibrotic and Anti-Inflammatory Activity of the Dual CCR2 and CCR5 Antagonist Cenicriviroc in a Mouse Model of NASH
|
| |
| |
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
E. Lefebvre1, T. Hashiguchi2, H. Jenkins1,
H. Yoneyama2, S.L. Friedman3, G.H.I. Wolfgang4
1Tobira Therapeutics, Inc., San Francisco, CA, USA; 2Stelic Institute & Co., Tokyo, Japan;
3Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, NY, USA; 4Kailua-Kona, HI, USA
|
| |
|
|
|
|
|
